I still haven’t seen any evidence of a novel coronavirus being properly isolated in a lab as per Koch’s Postulate, and that’s the only official scientific homologation of a virus. But “follow the science” is what the cry, so here’s the latest in 5G science, from US’ NIH website and PubMed.
5G Technology and induction of coronavirus in skin cells
In this research, we show that 5G millimeter waves could be absorbed by dermatologic cells acting like antennas, transferred to other cells and play the main role in producing Coronaviruses in biological cells. DNA is built from charged electrons and atoms and has an inductor-like structure. This structure could be divided into linear, toroid and round inductors. Inductors interact with external electromagnetic waves, move and produce some extra waves within the cells. The shapes of these waves are similar to shapes of hexagonal and pentagonal bases of their DNA source. These waves produce some holes in liquids within the nucleus. To fill these holes, some extra hexagonal and pentagonal bases are produced. These bases could join to each other and form virus-like structures such as Coronavirus. To produce these viruses within a cell, it is necessary that the wavelength of external waves be shorter than the size of the cell. Thus 5G millimeter waves could be good candidates for applying in constructing virus-like structures such as Coronaviruses (COVID-19) within cells.
1Instytut Medycyny Pracy im. prof. J. Nofera / Nofer Institute of Occupational Medicine, Łódź, Poland (Zakład Ochrony Radiologicznej / Department of Radiological Protection).
2Politechnika Wrocławska / Wrocław University of Sciences and Technology, Wrocław, Poland (Katedra Telekomunikacji i Teleinformatyki / Department of Telecommunications and Teleinformatics).
3Instytut Medycyny Pracy im. prof. J. Nofera / Nofer Institute of Occupational Medicine, Łódź, Poland (Zakład Fizjologii Pracy i Ergonomii / Department of Work Physiology and Ergonomics).
4Centralny Instytut Ochrony Pracy – Państwowy Instytut Badawczy / Central Institute for Labor Protection – National Research Institute, Warsaw, Poland (Zakład Bioelektromagnetyzmu / Department of Bioelectromagnetism).
5Wojskowy Instytut Higieny i Epidemiologii / Military Institute of Hygiene and Epidemiology, Warsaw, Poland.
6Instytut Medycyny Pracy im. prof. J. Nofera / Nofer Institute of Occupational Medicine, Łódź, Poland.
There is an ongoing discussion about electromagnetic hazards in the context of the new wireless communication technology – the fifth generation (5G) standard. Concerns about safety and health hazards resulting from the influence of the electromagnetic field (EMF) emitted by the designed 5G antennas have been raised. In Poland, the level of the population’s exposure to EMF is limited to 7 V/m for frequencies above 300 MHz. This limitation results from taking into account the protective measures related not only to direct thermal hazards, but also to diversified indirect and long-term threats. Many countries have not established legal requirements in this frequency range, or they have introduced regulations based on recommendations regarding protection against direct thermal risks only (Council Recommendation 1999/519/EC). For such protection, the permissible levels of electric field intensity are 20-60 V/m (depending on the frequency). This work has been created through an interdisciplinary collaboration of engineers, biologists and doctors, who have been for many years professionally dealing with the protection of the biosphere against the negative effects of EMF. It presents the state of knowledge on the biological and health effects of the EMF emitted by mobile phone devices (including millimeter waves which are planned to be used in the 5G network). A comparison of the EU recommendations and the provisions on public protection being in force in Poland was made against this background. The results of research conducted to date on the biological effects of the EMF radiofrequency emitted by mobile telecommunication devices, operating with the frequencies up to 6 GHz, do not allow drawing any firm conclusions; however, the research evidence is strong enough for the World Health Organization to classify EMF as an environmental factor potentially carcinogenic to humans. At the moment, there is a shortage of adequate scientific data to assess the health effects of exposure to electromagnetic millimeter waves, which are planned to be used in the designed 5G devices. Nevertheless, due to the fact that there are data indicating the existence of biophysical mechanisms of the EMF influence that may lead to adverse health effects, it seems necessary to use the precautionary principle and the ALARA principle when creating environmental requirements for the construction and exploitation of the infrastructure of the planned 5G system. Med Pr. 2020;71(1):105-13.
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Before we enter the official documents, please do the following experiment: Pick any number between 10 and 1000. Write it in an online search engine, followed by “new cases”. Watch hundreds and thousands of news pieces reporting that specific number of cases in hundreds different locations, especially US. Remember that 46% of the officially reported Covid-19 fatalities in US come from New York. Compare that with the distribution in the news. If you have basic knowledge of calculus, ask yourself: How many billions people have been reported in total? What volume of work was required for all that reporting, in a time when much of the media was laid off or working from home, while the volume of events/news was never higher?
This publication intends to provide a non-exhaustive overview of articles from the media and other available public sources. It does not reflect the views of the CAHAI and of the Council of Europe.
China, the first epicentre of this disease and renowned for its technological advance in this field, has tried to use this to its real advantage. Its uses seem to have included support for measures restricting the movement of populations, forecasting the evolution of disease outbreaks and research for the development of a vaccine or treatment. With regard to the latter aspect, AI has been used to speed up genome sequencing, make faster diagnoses, carry out scanner analyses or, more occasionally, handle maintenance and delivery robots (A. Chun, In a time of coronavirus, China’s investment in AI is paying off in a big way, South China Morning post, 18 March 2020).
Its contributions, which are also undeniable in terms of organising better access to scientific publications or supporting research, does not eliminate the need for clinical test phases nor does it replace human expertise entirely. The structural issues encountered by health infrastructures in this crisis situation are not due to technological solutions but to the organisation of health services, which should be able to prevent such situations occurring (Article 11 of the European Social Charter). Emergency measures using technological solutions, including AI, should also be assessed at the end of the crisis. Those that infringe on individual freedoms should not be trivialised on the pretext of a better protection of the population. The provisions of Convention 108+ should in particular continue to be applied.
The contribution of artificial intelligence to the search for a cure
The first application of AI expected in the face of a health crisis is certainly the assistance to researchers to find a vaccine able to protect caregivers and contain the pandemic. Biomedicine and research rely on a large number of techniques, among which the various applications of computer science and statistics have already been making a contribution for a long time. The use of AI is therefore part of this continuity.
The predictions of the virus structure generated by AI have already saved scientists months of experimentation. AI seems to have provided significant support in this sense, even if it is limited due to so-called “continuous” rules and infinite combinatorics for the study of protein folding. The American start-up Moderna has distinguished itself by its mastery of a biotechnology based on messenger ribonucleic acid (mRNA) for which the study of protein folding is essential. It has managed to significantly reduce the time required to develop a prototype vaccine testable on humans thanks to the support of bioinformatics, of which AI is an integral part.
Indeed, in the weeks following the appearance of the new coronavirus in Wuhan, China, in December 2019, nearly 2,000 research papers were published on the effects of this new virus, on possible treatments, and on the dynamics of the pandemic. This influx of scientific literature naturally reflects the eagerness of researchers to deal with this major health crisis, but it also represents a real challenge for anyone hoping to exploit it.
Microsoft Research, the National Library of Medicine and the Allen Institute for AI (AI2) therefore presented their work on 16 March 2020, which consisted of collecting and preparing more than 29,000 documents relating to the new virus and the broader family of coronaviruses, 13,000 of which were processed so that computers could read the underlying data, as well as information on authors and their affiliations. Kaggle, a Google subsidiary and platform that usually organisesdata science competitions, created challenges around 10 key questions related to the coronavirus. These questions range from risk factors and non-drug treatments to the genetic properties of the virus and vaccine development efforts. The project also involves the Chan Zuckerberg Initiative (named after Facebook founder Mark Zuckerberg and his wife Priscilla Chan) and Georgetown University’s Center for Security and Emerging Technologies (W. Knight, Researchers Will Deploy AI to Better Understand Coronavirus, Wired, March 17, 2020).
Artificial intelligence, observer and predictor of the evolution of the pandemic
The Canadian company BlueDot is credited with the early detection of the virus using an AI and its ability to continuously review over 100 data sets, such as news, airline ticket sales, demographics, climate data and animal populations. BlueDot detected what was then considered an outbreak of pneumonia in Wuhan, China on 31 December 2019 and identified the cities most likely to experience this outbreak (C. Stieg, How this Canadian start-up spotted coronavirus before everyone else knew about it, CNBC, March 3, 2020).
A team of researchers working with the Boston Children’s Hospital has also developed an AI to track the spread of the coronavirus. Called HealthMap, the system integrates data from Google searches, social media and blogs, as well as discussion forums: sources of information that epidemiologists do not usually use, but which are useful for identifying the first signs of an outbreak and assessing public response (A. Johnson, How Artificial Intelligence is Aiding the fight Against Coronavirus, Datainnovation, March 13, 2020).
The International Research Centre for Artificial Intelligence (IRCAI) in Slovenia, under the auspices of UNESCO, has launched an “intelligent” media watch on coronavirus called Corona Virus Media Watch which provides updates on global and national news based on a selection of media with open online information. The tool, also developed with the support of the OECD and the Event Registry information extraction technology, is presented as a useful source of information for policy makers, the media and the public to observe emerging trends related to Covid-19 in their countries and around the world.
Artificial intelligence to assist healthcare personnel
For their part, two Chinese companies have developed AI-based coronavirus diagnostic software. The Beijing-based start-up Infervision has trained its software to detect lung problems using computed tomography (CT) scans. Originally used to diagnose lung cancer, the software can also detect pneumonia associated with respiratory diseases such as coronavirus. At least 34 Chinese hospitals are reported to have used this technology to help them screen 32,000 suspected cases (T. Simonite, Chinese Hospitals Deploy AI to Help Diagnose Covid-19, Wired, February 26, 2020).
The Alibaba DAMO Academy, the research arm of the Chinese company Alibaba, has also trained an AI system to recognise coronaviruses with an accuracy claimed to be 96%. According to the company, the system could process the 300 to 400 scans needed to diagnose a coronavirus in 20 to 30 seconds, whereas the same operation would usually take an experienced doctor 10 to 15 minutes. The system is said to have helped at least 26 Chinese hospitals to review more than 30,000 cases (C. Li, How DAMO Academy’s AI System Detects Coronavirus Cases, Alizila, March 10, 2020).
In South Korea, AI is reported to have helped reduce the time needed to design testing kits based on the genetic make-up of the virus to a few weeks, when it would normally take two to three months. The biotech company Seegene used its automated test development system to develop the test kit and distribute it widely. Large-scale testing is indeed crucial to overcome containment measures and this testing policy seems to have contributed to the relative control of the pandemic in this country, which has equipped 118 medical establishments with this device and tested more than 230,000 people (I. Watson, S. Jeong, J. Hollingsworth, T. Booth, How this South Korean company created coronavirus test kits in three weeks, CNN World, March 13, 2020).
Artificial intelligence as a tool for population control
The example set by Singapore in its control of epidemic risks, with the support of technology, is certainly unique and difficult to export because of the social acceptance of restrictive safety measures: issue of a containment order for populations at risk, verification of compliance with the measures by mobile phone and geolocation, random home checks (K. Vaswani, Coronavirus: The detectives racing to contain the virus in Singapore, BBC News, 19 March 2020). AI has been quite widely used in support of such mass surveillance policies as in China, where devices have been used to measure temperature and recognize individuals or to equip law enforcement agencies with “smart” helmets capable of flagging individuals with high body temperature. Facial recognition devices have, however, experienced difficulties due to the wearing of surgical masks, leading one company to attempt to circumvent this difficulty since many services in China now rely on this technology, including state services for surveillance measures. Hanvon thus claims to have created a device to increase the recognition rate of wearers of surgical masks to 95% (M. Pollard, Even mask-wearers can be ID’d, China facial recognition firm says, Reuters, 9 March 2020). In Israel, a plan to use individual telephone follow-up to warn users not to mix with people potentially carrying the virus has been developed (A. Laurent, COVID-19: States use geolocalisation to know who respects containment, Usebk & Rica, 20 March 2020 – in French only). In South Korea, an alert transferred to the health authorities is triggered when people do not comply with the isolation period, for example by being in a crowded place such as on public transport or a shopping centre (Ibid.). In Taiwan, a mobile phone is given to infected persons and records their GPS location so that police can track their movements and ensure that they do not move away from their place of confinement (Ibid.). In Italy, a company has also developed a smartphone application that can be used to trace the itinerary of a person infected with the virus and warn people who have had contact with him or her. According to the designer, privacy would be guaranteed, as the application would not reveal phone numbers or personal data (E. Tebano, Coronavirus, pronta la app italiana per tracciare i contagi: ‘Così possiamo fermare l’epidemia’, Corriere della Sera, 18 March 2020) In Lombardy, telephone operators have made available data concerning the movement of mobile phones from one telephone terminal to another (M. Pennisi, Coronavirus, come funzionano il controllo delle celle e il tracciamento dei contagi. Il Garante: «Non bisogna improvvisare», Corriere della Sera, 20 March 2020).
In the United States, tension can be perceived between guaranteeing individual rights and protecting collective interests during this health crisis. Thus, the GAFAM have at their disposal in the United States information which would be extremely valuable in times of crisis: an immense amount of data on the American population. Larry Brilliant, an epidemiologist and executive director of Google.org, claims that he can “change the face of public health” and believes that “few things in life are more important than the question of whether major technologies are too powerful, but a pandemic is undoubtedly one of them” (N. Scola, Big Tech faces a ‘Big Brother’ trap on coronavirus, POLITICO, 18 March 2020). The U.S. government has therefore asked these companies to have access to aggregated and anonymous data, especially on mobile phones, in order to fight the spread of the virus (T. Romm, E. Dwoskin, C. Timberg, U.S. government, tech industry discussing ways to use smartphone location data to combat coronavirus, The Washington Post, March 18, 2020). However, these companies have been cautious in view of the legal risk and potential image damage (S. Overly, White House seeks Silicon Valley help battling coronavirus, POLITICO, 11 March 2020). Data regulation would likely have helped frame the public-private dialogue and determine what types of emergencies should be subject to the collective interest over individual rights (as well as the conditions and guarantees of such a mechanism), but Congress has made no progress in the last two years on such a law.
Finally, attempts at misinformation have proliferated on social networks and the Internet. Whether it concerns the virus itself, the way it spreads or the means to fight its effects, many rumours have circulated (“Fake news” and disinformation about the SARS-CoV2 coronavirus, INSERM, 19 February 2020). AI is a technology already used with some effectiveness by platforms to fight against inappropriate content. UNICEF adopted a statement on 9 March 2020 on misinformation about the coronavirus in which it intends to “actively take steps to provide accurate information about the virus by working with the World Health Organization, government authorities and online partners such as Facebook, Instagram, LinkedIn and TikTok, to ensure that accurate information and advice is available, as well as by taking steps to inform the public when inaccurate information appears”. The enactment of restrictive measures in Council of Europe member States to avoid fuelling public concern is also envisaged. However, the Council of Europe Committee of Experts on the Media Environment and Media Reform (MSI-REF) underlined in a statement of 21 March 2020 that “the crisis situation should not be used as a pretext to restrict public access to information. Nor should States introduce restrictions on media freedom beyond the limits allowed by Article 10 of the European Convention on Human Rights”. The Committee also highlights that “member States, together with all media actors, should strive to ensure an environment conducive to quality journalism”.
Artificial intelligence: an evaluation of its use in the aftermath of a crisis
Digital technology, including information technology and AI, are therefore proving to be important tools to help build a coordinated response to this pandemic. The multiple uses also illustrate the limits of what can currently be achieved by this very technology, which we cannot expect to compensate for structural difficulties such as those experienced by many health care institutions around the world. The search for efficiency and cost reduction in hospitals, often supported by information technology, should not reduce the quality of services or compromise universal access to care, even in exceptional circumstances.
It should be recalled that Article 11 of the European Social Charter (ratified by 34 of the 47 member States of the Council of Europe) establishes a right to health protection which commits the signatories “to take, either directly or in co-operation with public and private organisations, appropriate measures designed in particular to : 1°) to eliminate, as far as possible, the causes of ill-health; 2°) to provide consultation and education services for the improvement of health and the development of a sense of individual responsibility for health; 3°) to prevent, as far as possible, epidemic, endemic and other diseases, as well as accidents.”
Finally, it should be possible to evaluate the emergency measures taken at the end of the crisis in order to identify the benefits and issues encountered by the use of digital tools and AI. In particular, the temporary measures of control and mass monitoring of the population by this technology should not be trivialized nor become permanent (Y. N. Harari, Yuval Noah Harari: the world after coronavirus, The Financial Times, 20 March 2020).
Standards relating to data protection, such as Convention 108(+) of the Council of Europe, must still be applied fully and under all circumstances: whether it be the use of biometric data, geolocalisation, facial recognition or the use of health data. Use of emergency measures should be carried out in full consultation with data protection authorities and respect the dignity and the private life of the users. The different biases of the various types of surveillance operations should be considered, as these may cause significant discrimination (A.F. Cahn, John Veiszlemlein, COVID-19 tracking data and surveillance risks are more dangerous than their rewards, NBC News, 19 March 2020).
Executives from Amazon, Google, Microsoft, Apple and Facebook met officials at Downing Street on Wednesday to discuss their role in the coronavirus crisis. One of the things discussed was their role in “modelling and tracking data”. In similar meetings at the White House, meanwhile, companies were asked how they could use artificial intelligence. A World Health Organization report last month said AI and big data were a key part of China’s response to the virus.
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
I’m reporting from captivity in Agadir, a Moroccan city which I’ve just found out it’s the birth-place of Moncef Slaoui, the newly appointed head of “Operation Warp Speed” , Trump’s mass-vaccination campaign. And the that’s the least disturbing thing I have to tell you. I probably need protection now, I’m warned, authorities here are not big fans of free speech, people have been arrested for much less. But this isn’t much of a life anyway; all worth it if you spread this knowledge like fire. May the public eye be my protection, if any.
US President Donald Trump selected Moroccan immunology expert Moncef Slaoui to be the head of his administration’s COVID-19 vaccine development team, working on “Operation Warp Speed.”
The Moroccan expert, 60, will serve as the US government’s “therapeutics czar” to help coordinate the development of vaccines and treatments. The role is shared between the US Department of Health and Human Services and the Department of Defense.
Slaoui will be assisted by Army Gen. Gustave Perna, the commander of United States Army Materiel Command.
Trump’s new “Vaccine czar”, Dr. Slaoui’s appeal to open source vaccines (2015). Why just vaccines?
Slaoui earned a Ph.D. in molecular biology and immunology from the Free University of Brussels, Belgium, and completed his postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston.
He was the former head of the vaccines division at GlaxoSmithKline (GSK), where he oversaw the development of various vaccines: Rotarix, Synflorix, and Cervarix. In 2007, he announced plans to establish a neurosciences research group in Shanghai that would employ a thousand scientists and cost $100 million; it failed miserably and ceased operations in August 2017.
In 2008, Slaoui led the $720 million acquisition of Sirtris Pharmaceuticals, which folded in 2013. In 2012, he oversaw GSK’s purchase of Human Genome Sciences for over $3 billion. In 2015 he won European approval for the world’s first malaria vaccine (Mosquirix).
Trump’s “Vaccine Czar” sucking up to Joe Biden and foretelling our present! Rare interview 2016
When he retired from the drugmaker in 2017, GSK was still working on the vaccine for Ebola.
GSK is now working on a COVID-19 vaccine with Sanofi, the French multinational pharma giant.
“Not long after leaving GSK, the enthusiastic and outgoing Slaoui started joining biotech boards, with welcomes at SutroVax, mRNA player Moderna as well as the public outfit Intellia $NTLA, one of a handful of CRISPR/Ca9 gene editing startups dominating the field. Then, a little over a month ago, he dropped off the Intellia crew, citing a conflict but not explaining it.” – Endpoints
But his biggest business move was becoming a partner at Medicxi Capital, a biotechnology venture capital firm in the Philadelphia, Pennsylvania area.
Commenting on his new role as Partner at Medicxi, Dr Slaoui said: “I am looking forward to making an active contribution to selecting and leading investments, and to supporting ambitious entrepreneurs to develop medicines that ultimately make a difference to patients.”
Medicxi has built a highly experienced team and, through the scientific advisory boards (SABs) of each of its funds, has access to some of the most respected names in the pharma industry. As well as Medicxi’s senior team, now including Dr Slaoui, external members and observers on the SABs to Medicxi’s funds included (2017):
From Novartis:
Dr Vasant (Vas) Narasimhan, Global Head of Drug Development, Chief Medical Officer and Chief Executive Officer Elect
Dr Evan Beckman, Global Head of Translational Medicine at NIBR
Nigel Sheail, Head of Business Development and Licensing
From Verily Life Sciences:
Dr Andy Conrad, Chief Executive Officer
Dr Robert Califf, Advisor and former US FDA Commissioner
From GSK:
Dr Patrick Vallance President, R&D
Dr Paul-Peter Tak Senior Vice President R&D Pipeline, Global Development Leader and Chief Immunology Officer
From Johnson & Johnson:
Dr. Paul Stoffels, Executive Vice President, Chief Scientific Officer
Dr. Bill Hait, Global Head, Janssen Research & Development
Dr Patrick Verheyen Global Head, Janssen Business Development
Michèle Ollier, co-founder and Partner at Medicxi, said: “Moncef has made a tremendous contribution through his role on our SABs and we look forward to his continued energetic and insightful contribution as a Partner at Medicxi. Our SAB meetings are challenging, insightful and inspiring, and contribute hugely to how we steer and advise our portfolio companies.”
Medicxi is based in London, Geneva and Jersey. The Company’s mission is to invest across the full healthcare continuum. Medicxi was established by the former Index Ventures life sciences team. Medicxi manages the legacy life science portfolio of Index Ventures as well as the new funds launched as Medicxi, Medicxi Ventures 1 (MV1) and Medicxi Growth 1 (MG1) focusing on early-stage and late-stage investments in life sciences.
GSK, Johnson & Johnson and Novartis, three of the world’s largest pharmaceutical companies back Medicxi along with Verily, an Alphabet company. These companies, whilst participating in the SABs of the funds, do not receive any preferential rights to the portfolio companies.
Medicxi’s team has been investing in life sciences for over 20 years and has backed many successful companies, including Genmab (NASDAQ Copenhagen: GEN), PanGenetics (sold to AbbVie), Molecular Partners (SWX: MOLN), XO1 (sold to Janssen) Egalet (NASDAQ: EGLT), Minerva Neurosciences (NASDAQ: NERV) and Versartis (NASDAQ: VSAR).
Since 2017, Slaoui has been also sitting on the board of Moderna, a biotechnology company also pursuing a COVID-19 vaccine, based in Cambridge, Massachusetts.
The other problem, because they always come in pairs: Trump awarded Moderna almost $0.5Billion from public money a few days before nominating Slaoui. CNN reported on May 18th:
“Valera’s efforts (Moderna subsidiary) have resulted in the demonstration of preclinical efficacy of Moderna’s mRNA-based vaccines in multiple viral disease models, Moderna said.
In the partnership with the Gates Foundation, Valera will apply its mRNA vaccine platform as well as Moderna’s drug platform Messenger RNA Therapeutics™. Designed to produces human proteins, antibodies, and entirely novel protein constructs inside patient cells, the therapeutics are secreted or active intracellularly.” – Genetic Engineering & Biotechnology News
What, you think that’s bad? What if I told you this is the last one in a very long series of collaborations between the two?
I find most relevant this transhumanist project Slaoui worked on with Google from 2016, as reported by Bloomberg:
<<The recent partnership between GlaxoSmithKline (GSK) and Alphabet (Google) further opens the door for development in the biotechnology industry’s experimental “bioelectronics” segment. Chairman of Vaccines at GlaxoSmithKline Dr. Moncef Slaoui thinks the partnership could create an entirely new industry. “I think this is a whole new industry as big as the pharmaceutical industry … there’s a whole new world that we’re opening here which is dealing with electrical signals to connect with our biology and changes functioning,” Slaoui told CNBC’s Meg Tirrell on “Squawk Box” Monday morning. Calling Alphabet’s Verily Life Services a “really exciting partner,” Slaoui says GlaxoSmithKline shares “a very common vision of integrating electronics and big data analytics and technologies with medicines and biology.” “They bring to us the engineering capabilities, the electronics, the low power technologies and the wireless technologies that are critical to miniaturize these devices, power them and extract information from them,” Slaoui noted.>>
Trump’s new “Vaccine czar”, Dr Moncef Slaoui on bioelectronics, transhumanist medicine (2016)
“GSK has been interested in this field for years, and in 2013 announced a $1 million prize for innovative bioelectronics research. In a press statement, GSK’s Moncef Slaoui said: “Many of the processes of the human body are controlled by electrical signals firing between the nervous system and the body’s organs, which may become distorted in many chronic diseases.” He said bioelectronic seeks to “correct the irregular [electrical] patterns found in disease states, using miniaturized devices attached to individual nerves.” – The Verge
And having in mind the technological terror, the transhumanist/eugenicist obsessions brought by the coronavirus policy-makers today, one quote from the same source above hits home. This whole business falls right in the arms of anyone associating the coronavirus pandemic with human microchipping. Slaoui cited animal models as the indicator that bioelectronics can treat chronic diseases with a number of different devices.
The devices themselves are very small, about “the size of a rice grain”, and can “either stimulate or black the electric signals that our brains sense through our nerves to control the functioning of our organs… The limitations are around power as power requires energy and energy means heat and heat doesn’t go well with biology.
“High-Jacking our Biology with Electronics” – panel ft. Dr. Moncef Slaoui’s and more experts (2015)
It gets weirder
Slaoui rejected reports in late March of his involvement with a US government task force for COVID-19 vaccine development and denied as recently as May 11 any intention to work with the Trump administration. WHY?? Morocco World News reported in March 31st: “The doctor said he has no working arrangements with the US government in a statement to Moroccan French-language newspaper L’Economiste. Several local news outlets claimed that the former chairman of pharmaceutical giant GlaxoSmithKline (GSK) is part of a task force that is researching a vaccine to clamp down on the spread of the virus. The international expert is currently a member of the board of directors of American biotechnology company Moderna. Slaoui explained that he is part of the company’s research and development committee. The committee has received support from federal organizations to help fund the development of a COVID-19 vaccine. “
White House senior adviser Jared Kushner, the son-in-law of President Trump, was among the officials who interviewed Slaoui for the role.
Jared Kushner went there. Jared Kushner personally picked America’s new “Vaccine Czar” Moncef Slaoui precisely one year after the meeting. Jared Kushner is a Zionist. Jared Kushner is Trump’s son law.
To avoid a conflict of interest, Slaoui resigned from the board of the Massachusetts-based biotech firm Moderna, which had been developing a vaccine for the coronavirus. He stepped down but he didn’t give up his stakes in Moderna, as the Daily Beast reports:
“Slaoui’s ownership of 156,000 Moderna stock options, disclosed in required federal financial filings, sparked concerns about a conflict of interest. Democratic Massachusetts Senator Elizabeth Warren called Slaoui out over the matter on Twitter: “It is a huge conflict of interest for the White House’s new vaccine czar to own $10 million of stock in a company receiving government funding to develop a COVID-19 vaccine. Dr. Slaoui should divest immediately.” The company’s shares skyrocketed last month after news broke of the $483 million in federal funding to work on a coronavirus vaccine. Slaoui could not immediately be reached for comment on the matter.”
Slaoui also sits on the boards of SutroVax, the Biotechnology Innovation Organization, the International AIDS Vaccine Initiative, and the PhRMA Foundation
The Moroccan expert’s main contenders for the position of chief advisor at “Operation Warp Speed” were Algeria’s Elias Zerhouni and US’ Arthur Levinson.
Zerhouni, born in 1951, is an Algerian scientist, radiologist, and biomedical engineer. The expert has held several important positions in a number of institutions, ranging from medical schools to pharmaceutical companies and government task forces.
In 2009, under the Obama administration, Zerhouni served as the first science envoy in the US and worked towards fostering scientific and technological collaboration with other countries.
Between 2011 and 2018, as a final stage in his career, Zerhouni was the President for Global Research and Development at, well, Sanofi.
The third main candidate in the race for Trump’s COVID-19 operation, Arthur Levinson, is an American businessman specialized in biotechnology.
Levinson has served as senior advisor for several companies and institutions, including Swiss healthcare multinational Hoffmann-La Roche, Amyris Biotechnologies, the Memorial Sloan Kettering Cancer Center, the California Institute for Quantitative Biosciences, and Princeton University.
The American businessman is currently the chairman of tech giant Apple and CEO of biotechnology company Calico.
“We will get to [vaccines] eventually, but we’re not there yet. If we want to lift the lockdowns, we need to fully respect them first”
Outlook on the pandemic
During an interview on April 12, Slaoui said he expects life to begin its return to normal at the beginning of 2021 after global leaders rein in the pandemic, adding that he considers his prediction “optimistic.”
He is confident “that due to the high number of COVID-19 cases, clinical studies will reach results quickly.” He believes that “by the end of May or by early June, we will know if some of these drugs work.”
“I am very optimistic that we’ll have several vaccines for COVID-19. However, the problem is not having a vaccine. The problem is producing enough to protect eight billion people,” he continued.
Which is weird, because US Government has just announced same day spending $138mil. to turbo-boost vaccine production, and I’ve published a massive investigation piece on that.
In another interview with Moroccan television channel 2M on April 13, Slaoui forecast that the COVID-19 pandemic will heavily scar the global population.
“I believe that by 2021 our reality will not be completely back to normal but it will be improved,” he argued.
Moncef Slaoui said if the virus continues to spread, there will be no way to control it other than to create a vaccine and administer it on a massive scale.
“We will get to [vaccines] eventually, but we’re not there yet. If we want to lift the lockdowns, we need to fully respect them first,” he explained.
He said countries can phase out lockdowns when there is a proven COVID-19 treatment.
Slaoui acknowledged that there are now hundreds of clinical studies underway in many countries.
He expressed optimism that due to the increasing number of COVID-19 cases, clinical studies will achieve preliminary results quickly. “I believe that by the end of May or by early June, we will know if some of these drugs work.”
Government watchdog Public Citizen on Thursday “condemned the Trump administration’s reported appointment of a former pharmaceutical executive to the White House’s task force aimed at swiftly developing a Covid-19 vaccine as another example of the White House putting management of the pandemic in the hands of private industry. “
“If the Trump administration approaches vaccine development as it has Covid-19 prevention, testing, and treatment, the world may be in for years of more extraordinary pain,” Maybarduk added. “The dangers of global vaccine rationing are profound. No one corporation has the capacity to deliver a vaccine to all the world’s people.”
In March, Trump’s FDA came under fire for awarding monopoly status to Gilead Sciences for Remdesivir, a drug it was developing for Covid-19 treatment. The company backed off its claim after a pressure campaign led by Public Citizen.
“The U.S. government must commit to sharing clinical trial data, patents, and know-how among manufacturers and with the world, to quickly achieve the mountainous scale of production that humanity needs,” the group said.
Everything makes even more sense if you also read the first part of this series of articles dedicated to the covid mafia and Operation Warp Speed
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
#FlattenTheLies Face Mask by Silview MASKS ARE BAD FOR YOU, USE THEM ONLY IF YOU HAVE NO BETTER ALTERNATIVE! OR AT PROTESTS. AND IF YOU DO, USE ONE THAT SENDS OUT THE RIGHT MESSAGE.
Yes, from many reputable sources it comes out that 5G radiation can cause symptoms very similar to Covid-19’s, as many other things do. But that’s not the actual connection between 5G and Covid-19. They often appear to go hand in hand because it’s all about DATA.
From U.S. Department of Defense, Washington
Statement attributed to Lt. Col. Mike Andrews, Department of Defense spokesman: “Today (May 12th 2020) the Department of Defense and the U.S. Department of Health and Human Services, announce a $138 million contract with ApiJect Systems America for “Project Jumpstart” and “RAPID USA,” which together will dramatically expand U.S. production capability for domestically manufactured, medical-grade injection devices starting by October 2020.
Spearheaded by the DOD’s Joint Acquisition Task Force (JATF), in coordination with the HHS Office of the Assistant Secretary for Preparedness and Response, the contract will support “Jumpstart” to create a U.S.-based, high-speed supply chain for prefilled syringes beginning later this year by using well-established Blow-Fill-Seal (BFS) aseptic plastics manufacturing technology, suitable for combatting COVID-19 when a safe and proven vaccine becomes available.“
This was followed immediately by President Trump announcing he will mobilize military to distribute vaccines, when available.
ApiJect is a founding member of the Rapid Consortium. A YouTube video produced by the organization states, “These facilities will make enough prefilled syringes to inject every man, woman, and child in America with just the right dose 30 days after a vaccine becomes available. Plus every prefilled syringe can have an RFID chip attached. This will allow healthcare workers to use their mobile phones to automatically capture where and when every injection takes place, helping public health officials make more informed decisions.”
Photo Credit: Rapid Consortium Prefilled syringe with RFID chip attached
“Whether health officials are running a scheduled vaccination program or an urgent pandemic response campaign, they can make better decisions if they know when and where each injection occurs. With an optional RFID/NFC tag on each BFS prefilled syringe, ApiJect will make this possible. Before giving an injection, the healthcare worker will be able to launch a free mobile app and “tap” the prefilled syringe on their phone, capturing the NFC tag’s unique serial number, GPS location and date/time. The app then uploads the data to a government-selected cloud database. Aggregated injection data provides health administrators an evolving real-time “injection map.”
Now back to the Department of Defense statement:
“By immediately upgrading a sufficient number of existing domestic BFS facilities with installations of filling-line and technical improvements, “Jumpstart” will enable the manufacture of more than 100 million prefilled syringes for distribution across the United States by year-end 2020.
The contract also enables ApiJect Systems America to accelerate the launch of RAPID USA manufactured in new and permanent U.S.-based BFS facilities with the ultimate production goal of over 500 million prefilled syringes (doses) in 2021. This effort will be executed initially in Connecticut, South Carolina and Illinois, with potential expansion to other U.S.-based locations. RAPID will provide increased lifesaving capability against future national health emergencies that require population-scale vaccine administration on an urgent basis.
RAPID’s permanent fill-finish production capability will help significantly decrease the United States’ dependence on offshore supply chains and its reliance on older technologies with much longer production lead times. These supplies can be used if a successful SARS-COV-2 vaccine is oral or intranasal rather than injectable.”
ApiJect Systems America, Inc., a public benefit corporation based here, today announced that it has been awarded an HHS-DOD Title 3, DPA contract valued up to $138 million to accelerate the building of a new U.S.-based, high-speed, population-scale emergency drug injection capability with prefilled syringes from its subsidiary RAPID USA Inc. RAPID USA’s emergency program, “Project Jumpstart” is being initiated to supply 100 million prefilled syringes by year-end.
RAPID USA’s Project Jumpstart will immediately contract with a sufficient number of existing U.S.- based Blow-Fill-Seal (BFS) facilities to install filling lines and technical upgrades to enable production of prefilled syringes before year-end. BFS is a well-established high-speed medical- grade plastics aseptic manufacturing process that specializes in the high-volume production of pharmaceutical products. Jumpstart will also purchase and stockpile 100 million Needle Hubs for ApiJect prefilled syringes. Jumpstart will develop the capability to manufacture a minimum of 30 million prefilled syringes per month once therapeutic drugs and vaccines become available.
In parallel with Project Jumpstart, RAPID USA will build a network of 30 U.S.-based BFS manufacturing lines at three different, geographically dispersed, sites. Once operational, these 30 lines will fill, finish, and package up to 330 million prefilled BFS syringes per month. Initial production will begin in late 2021. RAPID USA will also build a U.S.-based training and prototyping facility capable of supporting 500 U.S.-based jobs at RAPID USA’s three manufacturing sites.
ApiJect Systems America CEO Jay Walker commented: “ApiJect’s Title 3, DPA funding gives our subsidiary RAPID USA the capability to swiftly create the domestic surge capacity in prefilled syringes that will be needed as therapeutics and vaccines become available. Project Jumpstart is the first stage in RAPID’s HHS-DOD supported two-stage effort. Within six months, Project Jumpstart will create a surge capacity to supply 100 million prefilled syringes and more than 500 million in 2021. Stage two, running in parallel with Jumpstart, will have RAPID USA building a network of 30 U.S.-based BFS manufacturing lines, enabling a monthly production of up to 330 million BFS prefilled syringes.”
Walker continued: “When discussions with HHS ASPR first began last year ApiJect was then focused on global health, specifically injection safety in low and middle-income countries where needle reuse and contaminated multi-dose vials kill as many as two million people every year and infect 10 million or more with transmissible diseases such as HIV and Hep-C. ASPR’s leadership wanted us to turn our attention to building a U.S.-based population-scale surge capacity for flexible biodefense purposes. We started immediately, and when COVID-19 emerged as a pandemic threat, our public-private partnership with HHS, which had been created in January, accelerated to focus on building both an emergency capability as well as longer-term sustainable injection surge capacity.”
Walker further commented: “RAPID USA is led by our multi-disciplinary team of experienced engineers, pharmaceutical technology experts, and management leadership. Our team is expending extraordinary efforts to ensure that when drugs are developed and tested all Americans can receive critical injections. We will have done our part by providing the manufacturing capacity to support the necessary volume of ready-to-use prefilled syringes that contain essential medicines, be they therapeutics or vaccines. Our public-private partnership, supported by Jefferies Financial Group, and the HHS-DOD Title 3 contract, demonstrates the vital role that RAPID will play in the war against COVID-19, as well as future national health emergencies.”
Rich Handler, CEO and Brian Friedman, President of Jefferies Financial Group, Inc., commented: “Finding a solution to the COVID-19 crisis demands the best from each of us, as companies and as individual citizens. When we learned what ApiJect was doing with the U.S. Government, Health and Human Services and the Department of Defense, we saw a role where Jefferies and our nearly 4,000 global professionals could make a difference. We invested in RAPID USA as we believe it is the right step at the right time, and we will continue to support ApiJect to assure RAPID USA can do their important job of building the surge capacity needed here on U.S. soil to help put this crisis behind us.”
#FlattenTheLies Face Mask by Silview MASKS ARE BAD FOR YOU, USE THEM ONLY IF YOU HAVE NO BETTER ALTERNATIVE! OR AT PROTESTS. AND IF YOU DO, USE ONE THAT SENDS OUT THE RIGHT MESSAGE.
ABOUT APIJECT AND RAPID USA
ApiJect Systems America, Inc., is a public benefit corporation dedicated to making injectable medicines safe and available for everyone. By building a network using high-speed, high-volume Blow-Fill-Seal medical grade plastics technology and an interlocking Needle Hub, ApiJect can supply hundreds of millions of ultra-low-cost prefilled syringes with optional RFID tags to enable GPS-based mobile tracking. ApiJect, along with the U.S. Department of Health and Human Services, is a founding member of the RAPID Consortium, a public-private partnership dedicated to giving the U.S. and the world the surge drug packaging it needs for addressing future pandemics and bio-emergencies. Learn more about ApiJect at www.apiject.com.
RAPID USA, Inc., a subsidiary of ApiJect Systems America, Inc., is building and will manage the high-speed, high volume surge capacity for drug fill, finish and packaging that America needs to effectively respond to future pandemics and bio-emergencies. Starting in the second half of 2021, RAPID USA will begin rolling out new U.S.-based BFS drug packaging lines that once completed in 2022, will provide the capacity to fill and finish up to 330 million prefilled syringes per month for the U.S. and the world. The HHS-DOD emergency program, Project Jumpstart, to supply the U.S. with 100 million BFS prefilled syringes by year-end, is a RAPID USA initiative. Learn more at www.rapidconsortium.com.
The inventor of ApiJect, the first BFS injection device, is Marc Koska, one of the world’s most respected and successful social entrepreneurs. “At 23 years of age, Marc Koska was living an idyllic lifestyle as a self-confessed beach bum’, sailing yachts around the Caribbean and generally having a good time. And although he had always thought he was destined to do something big, it took a trip back to the UK in 1984 to tell him what that something would be.
“I saw an article in The Guardian predicting the transmission of HIV through the re-use of syringes. And I thought, that’s what I’ve been waiting for!” Doctors were re-using syringes, and people were being infected with wholly preventable diseases by people in which they had enormous faith. “It was a nightmare situation.” So there and then he designed and put together a disposable syringe, which would automatically disable after its first use. Fast-forward 17 years from that seminal moment in May 1984, and Koska sold his first syringe after which there was no stopping him: he’s since sold 700 million.
But it wasn’t easy. The big manufacturers didn’t want it to progress, he says, and the World Health Organisation in Geneva weren’t much help either. They ignored the 23-year-old “dipstick” with a vision of a safe injection policy. Did they even say they liked the idea? “I don’t know, they told me to bugger off!” he chuckles. He doesn’t believe the market was ready for the product back then; as he says, he had to remove 100 bricks from his path to get to the stage today where his company, Star Syringe, is the biggest Auto Disable (AD) syringe manufacturer in the world.” – Money Week, 2006
In 2005, MARC founded the SafePoint Trust charity NGO “to educate children about the dangers of employing used needles.” Kept living from little fundings, presentations and mainly trying to hit the jackpot selling vials.
In 2015, Chinese WHO director, Dr. Margaret Chan announced a new global policy on injection safety, promoting auto-disable-syringes and Marc’s set for life. The K-1 is now licensed and manufactured by 14 global manufacturers. His biography gets a glorious “upgrade” in the Guardian, he was no more a former “beach bum”, actually in 1984, he “was working in the Caribbean, building forensic models to support murder cases,”
Among many other honors bestowed on Mr. Koska, he was made an Officer of the Order of the British Empire for his “contribution to global healthcare”. From a “beach bum” to royal honors.
All sponsored by Bill Gates and US Government, the top donors to WHO’s budget.
Rewiiiiind!
Din any red light blink when I mentioned Marc Koska’s benefactor, “Chinese WHO director, Dr. Margaret Chan”? Yes friends, the wife of the Ministry of Foreign Affairs of the People’s Republic of China, Dr. David Chan was running WHO at the time and relaunching Marc’s career, after many years in which they ignored his intense lobbying. Should it be because of a little improvement added to the product design – the RFID chip?
A few words on Jay Walker, who leads ApiJect’s technology efforts, as well as its business and commercialization activities. He is best known as the founder of Priceline and curator of TEDMED. Yes, TED is ran by Pharma suits too, Bill Gates funded them and one more of their guys is in Apiject, alongside a former GlaxoSmithKlein executive and other Pharma troopers, according to their own website, already linked above. So, of course, TED platformed this business and you can find Koska speaking there in 2010.
“Global Legislation”
A serial entrepreneur, Mr. Walker has founded three companies that have gone from launch to 50 million customers each. Mr. Walker is the world’s 10th most patented inventor, with more than 750 issued U.S. patents in technology-related fields.
Active in the field of medicine since 2012, Mr. Walker serves as chairman and curator of TEDMED, the health and medicine edition of the world-famous TED Conference. He is also Chairman of Upside, a travel and technology company that serves the unmanaged business traveler. A passionate student and practitioner of imagination, Mr. Walker founded and curated the Library of the History of Human Imagination, which Wired Magazine called, “the most amazing private library in the world.”
Bottom line: All the data collected by these RFID’s, the thermal scanning drones, the tracking, all the technological carnival around coronavirus and vaccines seems to be the actual agenda, not health, and it all needs 5G. This vaccination campaign proves to be more about data, surveillance and control, so 5G has to follow with it. US and China may fight on TV, but have collaborated on this at least since the times Fauci was funding Wuhan labs with American taxpayer money. They may have different propaganda shows on TV, but on the field US follows China’s footsteps with Chinese collaboration and know-how. WHO offered the “Umbrella Corporation” under which apparent enemies could collaborate for common population and resources control agendas.
Original post from April 2009 with my additional comment from April 5th 2020
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
A computer model developed in 1973 by a team of MIT researchers commissioned by the Club of Rome has predicted the “end of civilised life as we know it” by 2040, with a major change coming in 2020
The prediction came from a programme nicknamed World One, which was developed by a team of MIT researchers and processed by Australia’s largest computer.
It was originally devised by computer pioneer Jay Forrester, after he was tasked by the Club of Rome to develop a model of global sustainability.
However, the shocking result of the computer calculations showed that the level of pollution and population would cause a global collapse by 2040. The eerie calculation has been remarkably accurate in certain predictions, such as a stagnated quality of life and diminishing pool of natural resources. At this time the broadcasters addreses the audience: “At around 2020, the condition of the planet becomes highly critical. If we do nothing about it, the quality of life goes down to zero. Pollution becomes so seriously it will start to kill people, which in turn will cause the population to diminish, lower than it was in the 1900. At this stage, around 2040 to 2050, civilised life as we know it on this planet will cease to exist.”
Alexander King, a British pioneer who led the Club of Rome, also made a shocking prediction regarding national sovereignty. He told ABC:
“Sovereignty of nations is no longer absolute. There is a gradually diminishing of sovereignty, little bit by little bit. Even in the big nations, this will happen.”
#FlattenTheLies Face Mask by Silview MASKS ARE BAD FOR YOU, USE THEM ONLY IF YOU HAVE NO BETTER ALTERNATIVE! OR AT PROTESTS. AND IF YOU DO, USE ONE THAT SENDS OUT THE RIGHT MESSAGE.
World One, the computer program, looked at the world as one system. The report called it “an electronic guided tour of our behavior since 1900 and where that behavior will lead us.” The program produced graphs that showed what would happen to the planet decades into the future. It plotted statistics and forecasts for such variables as population, quality of life, the supply of natural resources, pollution, and more. Following the trend lines, one could see where the crises might take place.
As one measure to prevent catastrophe, the Club of Rome predicted some nations like the U.S. would have to cut back on their appetites for gobbling up the world’s resources. It hoped that in the future world, prestige would stem from “low consumption”—one fact that has so far not materialized. Currently, nine in ten people around the world breathe air that has high levels of pollution, according to data from the World Health Organization (WHO). The agency estimates that 7 million deaths each year can be attributed to pollution.
ABC’s This Day Tonight aired this story on 9 November, 1973
As always with widely publicised predictions, the main question to be solved is: Prediction, programming or predictive programming?
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
Quarantined & Bored? We have just the best time-killing machine ever!
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
#FlattenTheLies Face Mask by Silview MASKS ARE BAD FOR YOU, USE THEM ONLY IF YOU HAVE NO BETTER ALTERNATIVE! OR AT PROTESTS. AND IF YOU DO, USE ONE THAT SENDS OUT THE RIGHT MESSAGE.
